# List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>After Page No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Cutaway of Human skin</td>
<td>7</td>
</tr>
<tr>
<td>1.2</td>
<td>Cross-sectional view of human skin (full thickness)</td>
<td>7</td>
</tr>
<tr>
<td>1.3</td>
<td>A simplified model of the human skin</td>
<td>7</td>
</tr>
<tr>
<td>1.4</td>
<td>Electron micrograph of stratum corneum</td>
<td>7</td>
</tr>
<tr>
<td>1.5</td>
<td>The &quot;brick and mortar&quot; model of the stratum corneum</td>
<td>8</td>
</tr>
<tr>
<td>1.6</td>
<td>Vascular Supply to Skin</td>
<td>11</td>
</tr>
<tr>
<td>1.7</td>
<td>Events governing percutaneous absorption</td>
<td>13</td>
</tr>
<tr>
<td>1.8</td>
<td>Reservoir type transdermal drug delivery system</td>
<td>19</td>
</tr>
<tr>
<td>1.9</td>
<td>Drug-in-adhesive transdermal drug delivery system</td>
<td>19</td>
</tr>
<tr>
<td>1.10</td>
<td>Matrix-type transdermal drug delivery system</td>
<td>19</td>
</tr>
<tr>
<td>1.11</td>
<td>Microreservoir transdermal drug delivery system</td>
<td>20</td>
</tr>
<tr>
<td>1.12</td>
<td>Multilaminate drug-in-adhesive transdermal drug delivery system</td>
<td>20</td>
</tr>
<tr>
<td>1.13</td>
<td>Valia-Chien (V-C) Skin permeation cell</td>
<td>23</td>
</tr>
<tr>
<td>1.14</td>
<td>Ghannam-Chien (G-C) Membrane Permeation cell</td>
<td>23</td>
</tr>
<tr>
<td>1.15</td>
<td>Franz Diffusion Cell</td>
<td>23</td>
</tr>
<tr>
<td>1.16</td>
<td>Keshany-Chien (K-C) Skin Permeation Cell</td>
<td>23</td>
</tr>
<tr>
<td>1.17</td>
<td>Jhawer-Lord (J-L) rotating-disk system</td>
<td>23</td>
</tr>
<tr>
<td>3.1</td>
<td>Infrared absorption spectrum of Atenolol a) Sample b) Reference c) Overlap</td>
<td>52</td>
</tr>
<tr>
<td>3.2</td>
<td>Mass spectrum of Atenolol (Sample)</td>
<td>52</td>
</tr>
<tr>
<td>3.3</td>
<td>Mass spectrum of Atenolol (Reference)</td>
<td>52</td>
</tr>
<tr>
<td>3.4</td>
<td>Proton nuclear magnetic resonance spectra of Atenolol (Sample)</td>
<td>52</td>
</tr>
<tr>
<td>3.5</td>
<td>Proton nuclear magnetic resonance spectra of Atenolol (Reference)</td>
<td>52</td>
</tr>
<tr>
<td>3.6</td>
<td>Differential scanning colorimetry thermogram of Atenolol (Sample)</td>
<td>52</td>
</tr>
<tr>
<td>3.7</td>
<td>Differential scanning colorimetry thermogram of Atenolol (Reference)</td>
<td>52</td>
</tr>
<tr>
<td>3.8</td>
<td>Ultraviolet absorption spectrum of Atenolol</td>
<td>53</td>
</tr>
<tr>
<td>3.9</td>
<td>Linearly regressed standard curve of Atenolol in saline phosphate buffer pH 4.5</td>
<td>55</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>After Page No</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>3.10</td>
<td>Linearly regressed standard curve of Atenolol in saline phosphate buffer pH 7.4</td>
<td>55</td>
</tr>
<tr>
<td>3.11</td>
<td>Chromatogram of Atenolol in plasma</td>
<td>55</td>
</tr>
<tr>
<td>3.12</td>
<td>Linearly regressed standard curve of Atenolol in Plasma</td>
<td>56</td>
</tr>
<tr>
<td>3.13</td>
<td>Infrared absorption spectrum of Metoprolol tartrate a) Sample b) Reference c) Overlap</td>
<td>60</td>
</tr>
<tr>
<td>3.14</td>
<td>Mass spectrum of Metoprolol tartrate (Sample)</td>
<td>60</td>
</tr>
<tr>
<td>3.15</td>
<td>Mass spectrum of Metoprolol tartrate (Reference)</td>
<td>60</td>
</tr>
<tr>
<td>3.16</td>
<td>Differential scanning colorimetry thermogram of Metoprolol tartrate (Sample)</td>
<td>60</td>
</tr>
<tr>
<td>3.17</td>
<td>Differential scanning colorimetry thermogram of Metoprolol tartrate (Reference)</td>
<td>60</td>
</tr>
<tr>
<td>3.18</td>
<td>Ultraviolet absorption spectrum of Metoprolol tartrate</td>
<td>61</td>
</tr>
<tr>
<td>3.19</td>
<td>Linearly regressed standard curve of Metoprolol tartrate in saline phosphate buffer pH 4.5</td>
<td>62</td>
</tr>
<tr>
<td>3.20</td>
<td>Linearly regressed standard curve of Metoprolol tartrate in saline phosphate buffer pH 7.4</td>
<td>62</td>
</tr>
<tr>
<td>3.21</td>
<td>Chromatogram of Metoprolol tartrate in plasma</td>
<td>63</td>
</tr>
<tr>
<td>3.22</td>
<td>Linearly regressed standard curve of Metoprolol tartrate in Plasma</td>
<td>64</td>
</tr>
<tr>
<td>4.1</td>
<td>In vitro skin permeation profile of Atenolol (Linearly regressed)</td>
<td>79</td>
</tr>
<tr>
<td>4.2</td>
<td>In vitro skin permeation profile of Metoprolol tartrate (Linearly regressed)</td>
<td>79</td>
</tr>
<tr>
<td>4.3</td>
<td>Thin layer chromatography of skin homogenates incubated with Atenolol</td>
<td>81</td>
</tr>
<tr>
<td>4.4</td>
<td>Thin layer chromatography of skin homogenates incubated with Metoprolol tartrate</td>
<td>81</td>
</tr>
<tr>
<td>4.5</td>
<td>Instrument for the measurement of Tensile strength of polymeric films</td>
<td>93</td>
</tr>
<tr>
<td>4.6</td>
<td>Instrument for the measurement of Hardness of polymeric films</td>
<td>94</td>
</tr>
<tr>
<td>6.1</td>
<td>In vitro Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.2</td>
<td>In vitro Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.3</td>
<td>In vitro Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>After Page No</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>6.4</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.5</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.6</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.7</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.8</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.9</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.10</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.11</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.12</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.13</td>
<td><em>In vitro</em> Atenolol release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>125</td>
</tr>
<tr>
<td>6.14</td>
<td><em>In vitro</em> Metoprolol tartrate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.15</td>
<td><em>In vitro</em> Metoprolol tartrate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.16</td>
<td><em>In vitro</em> Metoprolol tartrate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.17</td>
<td><em>In vitro</em> Metoprolol tartrate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>After Page No</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>6.18</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.19</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.20</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.21</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.22</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.23</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.24</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.25</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.26</td>
<td><em>in vitro</em> Metoprolol tartarate release profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug released vs time.</td>
<td>127</td>
</tr>
<tr>
<td>6.27</td>
<td><em>in vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.28</td>
<td><em>in vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.29</td>
<td><em>in vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.30</td>
<td><em>in vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.31</td>
<td><em>in vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>After Page No</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>6.32</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.33</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.34</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.35</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.36</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.37</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.38</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.39</td>
<td><em>In vitro</em> Atenolol skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>129</td>
</tr>
<tr>
<td>6.40</td>
<td><em>In vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>131</td>
</tr>
<tr>
<td>6.41</td>
<td><em>In vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>131</td>
</tr>
<tr>
<td>6.42</td>
<td><em>In vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>131</td>
</tr>
<tr>
<td>6.43</td>
<td><em>In vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>131</td>
</tr>
<tr>
<td>6.44</td>
<td><em>In vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>131</td>
</tr>
<tr>
<td>6.45</td>
<td><em>In vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated vs time.</td>
<td>131</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>After Page No</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>---------------</td>
</tr>
<tr>
<td>6.46</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>6.47</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>6.48</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>6.49</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>6.50</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>6.51</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>6.52</td>
<td><em>in vitro</em> Metoprolol tartrate skin permeation profile of matrix diffusion controlled TDDS. Inset log-log graph of cumulative drug permeated <em>vs</em> time.</td>
<td>131</td>
</tr>
<tr>
<td>7.1</td>
<td>Effect of accelerated stability conditions on tensile strength for Atenolol matrix diffusion controlled TDDS.</td>
<td>145</td>
</tr>
<tr>
<td>7.2</td>
<td>Effect of accelerated stability conditions on moisture content for Atenolol matrix diffusion controlled TDDS.</td>
<td>145</td>
</tr>
<tr>
<td>7.3</td>
<td>Effect of accelerated stability conditions on drug content for Atenolol matrix diffusion controlled TDDS.</td>
<td>145</td>
</tr>
<tr>
<td>7.4</td>
<td>Effect of accelerated stability conditions on skin permeation rate for Atenolol matrix diffusion controlled TDDS.</td>
<td>145</td>
</tr>
<tr>
<td>7.5</td>
<td>Effect of accelerated stability conditions on tensile strength for Metoprolol tartrate matrix diffusion controlled TDDS.</td>
<td>147</td>
</tr>
<tr>
<td>7.6</td>
<td>Effect of accelerated stability conditions on moisture content for Metoprolol tartrate matrix diffusion controlled TDDS.</td>
<td>147</td>
</tr>
<tr>
<td>7.7</td>
<td>Effect of accelerated stability conditions on drug content for Metoprolol tartrate matrix diffusion controlled TDDS.</td>
<td>147</td>
</tr>
<tr>
<td>7.8</td>
<td>Effect of accelerated stability conditions on skin permeation rate for Metoprolol tartrate matrix diffusion controlled TDDS.</td>
<td>147</td>
</tr>
<tr>
<td>8.1</td>
<td>Atenolol-Plasma profile following the oral administration and topical application of matrix diffusion controlled TDDS.</td>
<td>153</td>
</tr>
<tr>
<td>8.2</td>
<td>Atenolol-Plasma profile following the oral administration and topical application of matrix diffusion controlled TDDS.</td>
<td>153</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>After Page No</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>8.3</td>
<td>Metoprolol tartarate-Plasma profile following the oral administration and topical application of matrix diffusion controlled TDDS.</td>
<td>154</td>
</tr>
<tr>
<td>8.4</td>
<td>Metoprolol tartarate-Plasma profile following the oral administration and topical application of matrix diffusion controlled TDDS.</td>
<td>154</td>
</tr>
</tbody>
</table>